EUCTR2019-000258-76-ES进行中（未招募）1 期
A single-dose, open-label, randomised, three-way crossover study to assess the comparative bioavailability of Captopril oral solution 5 mg/mL relative to captopril tablets and to investigate the effect of food on the pharmacokinetics of Captopril oral solution in healthy adult volunteers
Proveca Ltd.0 个研究点目标入组 24 人开始时间: 2019年10月21日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Signed informed consent including data protection declaration prior to study participation.
- •2.Healthy male and female volunteers. Women of childbearing potential (pre-menopausal, not surgically sterile for at least 3 months prior to the time of screening) must use a highly effective contraceptive method throughout the study such as: implants, injectables, hormonal contraceptives and condom or double barrier contraception (i.e., condom + diaphragm/spermicidal gel or foam), sexual abstinence or vasectomised partner and must have a confirmed negative pregnancy test at Screening Visit. Men must use safe contraceptive measures (i.e., condom/spermicidal gel or foam, sexual abstinence or be vasectomised) during the study.
- •3.Subjects aged =18 and =55 years at screening.
- •4.Caucasian (at least one parent of Caucasian origin).
- •5.Body Mass Index =18.5 and =30.0 kg/m2.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 24
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.History or presence of any clinically significant gastrointestinal pathology (e.g., chronic diarrhea, inflammatory bowel disease, major surgery of the gastrointestinal tract, gastroduodenal ulcer, or previous or active gastrointestinal bleeding), unresolved gastrointestinal symptoms (e.g., diarrhoea, vomiting), liver or kidney disease or other conditions known to interfere with the absorption, distribution, metabolism or excretion of the drug.
- •2.Any clinically significant abnormality identified on physical examination, laboratory tests, ECG or vital signs at the time of screening that in the judgment of the Investigator would preclude safe completion of the study or constrain pharmacokinetic assessment.
- •3.History or presence of asthma (including aspirin-induced asthma) or nasal polyps.
- •4.History of angioneurotic oedema associated with previous ACE (angiotensin-1 converting enzyme) inhibitor therapy, or hereditary/idiopathic angioneurotic oedema.
- •5.Any planned procedures, diagnostic tests or hospital admissions during the study duration.
- •6.Positive results of HBsAg, anti-HCV, anti-HIV tests.
- •7.Intake or administration of any systemic or topical medication (including multivitamin or mineral preparations), OTC (over the counter) or herbal dietary supplements (e.g., St. John's Worth, kava kava), within 4 weeks prior to the start of the study, when the terminal elimination half-life of these products does not allow for their complete elimination from the body before the beginning of the study. An exception is hormonal contraceptives for women with childbearing potential.
- •8.History of severe allergy or allergic reactions to the study drug or related drugs (any other ACE inhibitor) and products (including excipients of the formulations, for example lactose).
- •9.History of significant alcohol abuse within six months of the Screening Visit or any indication of the regular use of more than two units of alcohol per day (1 unit = 150 mL of wine or 360 mL of beer or 45 mL of 40% alcohol).
- •10.Presence of metabolites of illicit drugs in urine during screening procedures.
- •11.Breastfeeding.
- •12.Smoking.
- •13.Blood donation within 3 months prior to administration of the study medication.
- •14.Use of an investigational drug or participation in an investigational study within 90 days prior to administration of the study medication.
- •15.Volunteers in custody by juridical or official order.
- •16.Volunteers who have difficulties in understanding the language in which the volunteer information is given.
- •17.Volunteers who do not agree to the transmission of their anonymous data within the liability of documentation and notification.
- •18.Staff of the study centre, staff of the Sponsor or CRO, the Investigator himself or close relatives of the Investigator.
研究者
相似试验
尚未招募
不适用
A randomized, open-label, single dose, three-way crossover clinical trial to investigate the pharmacokinetics incorporating a comparison of fed/fasted pharmacokinetics of HIP1402 in healthy male volunteersDiseases of The genitoruinary systemKCT0001610Hanmi Pharm24
已完成
不适用
A single-dose, open label, randomized, three-way cross-over study in healthy volunteers to characterize the pharmacokinetics of the 300 mg trientine capsule and to assess the effect of dissolution rate and the effect of food on the pharmacokinetics of trientine.NL-OMON46237nivar BV24
已完成
不适用
Relative bioavailability of clopidogrel 75mg from two tablet formulations of SB224326 relative to one 75mg reference tablet of clopidogrel in healthy adult human subjects under fasting conditionsCTRI/2016/04/006789GlaxoSmithKline Research and Development Limited18
进行中（未招募）
不适用
Clinical study to test that the drug CHF 1535 100/6 (fixed combination of an anti-inflammatory drug and relaxing airways drug) delivered via pressurized inhaler using or not a spacer device is as effective in adolescent population as the licensed free combination of the same substances and compare it with administration in adults.MedDRA version: 14.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2011-005108-14-PLChiesi Farmaceutici S.p.A.
招募中
不适用
Relative bioavailability of montelukast sodium 5mg from two candidate chewable tablet formulations of GW483100 relative to one 5mg chewable tablet of reference montelukast sodium in healthy adult subjects under fasting conditionsCTRI/2015/03/005625GlaxoSmithKline Research and Development Limited18